By Salim S. Abdool Karim, M.B., Ch.B., Ph.D., and Nikita Devnarain, Ph.D. In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the...
FAMOTIDINE SHOWN TO SIGNIFICANTLY DECREASE COVID SYMPTOMS IN 55-PATIENT RANDOMIZED TRIAL
Famotidine, the over-the-counter heartburn drug, pepcid, was shown to significantly decrease COVID symptoms in a 55-patient randomized trial authored by Dr. Tobias Janowitz and published in the BMJ journal Gut February 10, 2022. Famotidine has been...
Honduras Reduced COVID Deaths With Repurposed Drugs, Early Treatment
Dr. Fernando Valerio, a critical care doctor in Honduras who co-authored a recent peer-reviewed study indicating the potential of repurposed drugs targeting SARS-CoV-2, shared with Trial Site his experience treating patients in the Central American nation....
Concern as Republicans push to make dubious Covid cure prescriptions easier
Ivermectin and hydroxychloroquine, the cures in question, have proven to be ineffective in preventing or treating Covid-19 By Eric Berger Republican state lawmakers across the United States have proposed – and in some cases passed – legislation that they say keeps the...
University of Calgary Repurposed Drug Breakthrough: Hydroxychloroquine Delays Severe Forms of Multiple Sclerosis
What if a relatively low-cost, repurposed drug could help treat multiple sclerosis (MS), the least treatable of all autoimmune diseases? That could be a distinct possibility now that Dr. Marcus Koch, MD, Ph.D., and Dr. Wee Yong, Ph.D., with Cummings School of Medicine...
Merck Inks Deal with Bangladeshi Pharma to Distribute Molnupiravir to 100+ Countries Targeting Important COVID-19 Antiviral Market
With a great demand for antivirals targeting early-onset COVID-19, Merck inked a sub-licensing deal with one of the largest pharmaceutical companies in Bangladesh to produce Molnupiravir (Lagevrio) for distribution to over 100 nations. The deal, part of the Medicine...
Naltrexone a potential therapeutic candidate for COVID-19
By Abhinav Choubey ~ Originally Published in Journal of Biomolecular Structure and Dynamics ~ Sept 15, 2021 Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease (COVID-19) that has resulted in a global pandemic. At...
Fluvoxamine: A Review of Its
Mechanism of Action and Its Role in COVID-19
By Vikas P. Sukhatme ~ Originally published in Frontiers in Pharmacology ~ April 20, 2021 Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized...
Fluvoxamine Information
Link to PDF
Colchicine Flops for In-Hospital COVID
— No reduced risk of mechanical ventilation or death by Zaina Hamza Colchicine (Colcrys) didn't benefit patients hospitalized with moderate to severe COVID-19-related pneumonia, researchers found in the COLCOVID randomized trial. Among more than 1,200 COVID-19...
Doctor Submits Fluvoxamine EUA Application to FDA
— Group of physician-scientists believes data support authorization for treating COVID-19 by Sophie Putka t took about 4 days for David Boulware, MD, MPH, to write the FDA emergency use authorization (EUA) application for fluvoxamine. Yes, a doctor wrote an EUA...
Widespread Access to Merck’s Molnupiravir in Philippines Even Though Drug Isn’t Authorized on Emergency Basis nor Approved
While a Phase 3 clinical trial investigating Merck’s molnupiravir in the Philippines seeks patients this isn’t a surprise given the imminent accessibility the drug now has to the local patient market. Currently allowed for compassionate use at several Philippines...
The Intriguing Potential of Available, Low Cost Drug for Alcoholism as Antiviral Against COVID-19
In what could be considered a striking discovery researchers form Harvard Medical School and Boston Children’s Hospital found that people taking the alcoholism drug disulfiram were 34% less likely to succumb to a SARS-CoV-2 infection, the virus behind COVID-19....
Common antidepressant may reduce COVID-19 death risk
By Katharine Lang Evidence is growing that a common antidepressant may reduce the severity of symptoms and mortality following SARS-CoV-2 infection.In an observational study, patients taking selective serotonin reuptake inhibitors (SSRIs) were 8% less likely to die...
Double standards? Dr. Mobeen Syed reviews the hurdles faced by ivermectin and molnupiravir in the COVID pandemic
Dr. Mobeen Syed aka “Dr. Been” has become a sensation on YouTube educating millions on various medical topics during this difficult pandemic including refreshingly sincere lessons on topics such as ivermectin. Most recently the online doc raised concern over...